MedTrace Logo

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

NCT05290493 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-02-10

Study results available
· View outcomes & findings →

Summary

This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric symptoms.

Conditions

  • 22q11 Deletion Syndrome

Interventions

DRUG

NB-001

Non-stimulant modulator of metabotropic glutamate receptors (mGluRs)

OTHER

Placebo

Matching, inactive placebo

Sponsors & Collaborators

  • Nobias Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2023-06-01
Completion
2023-06-09
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05290493 on ClinicalTrials.gov